Abstract
The mammalian target of rapamycin (mTOR) kinase is positioned at the juncture of several pathways regulating cell growth and proliferation. It is the downstream effector of the oncogenic PI3K/Akt pathway and is a key regulator of translational initiation. Accumulating data support mTORs role in lymphomagenesis, and its inhibition in preclinical models leads to lymphoma regression. The rationale for testing mTOR inhibitors in patients with lymphoma is evident, and early clinical data is promising. Along with the prototype of mTOR inhibitors, rapamycin, there are three mTOR inhibitors furthest along in development: temsirolimus, everolimus, and AP23573. These agents are emerging as well-tolerated drugs with encouraging preliminary activity. Here we review the rationale for testing mTOR inhibitors in lymphoma, the phase 1 trials influencing dose and schedule of mTOR inhibitors, and summarize the clinical results in obtained to date in patients with lymphoma.
Keywords: mTOR, mTOR inhibitors, non-Hodgkin lymphoma, rapamycin, clinical trials, pharmacokinetics
Reviews on Recent Clinical Trials
Title: Clinical Development of mTOR Inhibitors: A Focus on Lymphoma
Volume: 2 Issue: 2
Author(s): Sonali M. Smith
Affiliation:
Keywords: mTOR, mTOR inhibitors, non-Hodgkin lymphoma, rapamycin, clinical trials, pharmacokinetics
Abstract: The mammalian target of rapamycin (mTOR) kinase is positioned at the juncture of several pathways regulating cell growth and proliferation. It is the downstream effector of the oncogenic PI3K/Akt pathway and is a key regulator of translational initiation. Accumulating data support mTORs role in lymphomagenesis, and its inhibition in preclinical models leads to lymphoma regression. The rationale for testing mTOR inhibitors in patients with lymphoma is evident, and early clinical data is promising. Along with the prototype of mTOR inhibitors, rapamycin, there are three mTOR inhibitors furthest along in development: temsirolimus, everolimus, and AP23573. These agents are emerging as well-tolerated drugs with encouraging preliminary activity. Here we review the rationale for testing mTOR inhibitors in lymphoma, the phase 1 trials influencing dose and schedule of mTOR inhibitors, and summarize the clinical results in obtained to date in patients with lymphoma.
Export Options
About this article
Cite this article as:
Smith M. Sonali, Clinical Development of mTOR Inhibitors: A Focus on Lymphoma, Reviews on Recent Clinical Trials 2007; 2 (2) . https://dx.doi.org/10.2174/157488707780599366
DOI https://dx.doi.org/10.2174/157488707780599366 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strategies for Biology- and Molecular-Based Treatment of Myelodysplastic Syndromes
Current Drug Targets Myelodysplastic/Myeloproliferative Neoplasms
Current Cancer Therapy Reviews Texaphyrins: Tumor Localizing Redox Active Expanded Porphyrins
Anti-Cancer Agents in Medicinal Chemistry Distinct Epigenetic Reprogramming, Mitochondrial Patterns, Cellular Morphology, and Cytotoxicity after Bee Venom Treatment
Recent Patents on Anti-Cancer Drug Discovery Apoptosis Signalling Activated by TNF in the Lower Gastrointestinal Tract-Review
Current Pharmaceutical Biotechnology Role of Molecular Hydrogen in Skin Diseases and its Impact in Beauty
Current Pharmaceutical Design Multiple Roles of Annexin A2 in Post-Transcriptional Regulation of Gene Expressio
Current Protein & Peptide Science Histone Modifications, Stem Cells and Prostate Cancer
Current Pharmaceutical Design The Effects of Insulin and Insulin-Like Growth Factors on Tumor Vascularization: New Insights of Insulin-Like Growth Factor Family in Cancer
Current Medicinal Chemistry Synthesis, Characterization, and Molecular Structure of a Novel Zinc (II) Complex: Assessment of Impact of MDR1Pgp Expression on its Cytotoxic Activity
Medicinal Chemistry Therapeutic Value of Black Seed Oil in Methotrexate Hepatotoxicity in Egyptian Children with Acute Lymphoblastic Leukemia
Infectious Disorders - Drug Targets Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Current Drug Delivery Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry The Synthesis of Nano-Doxorubicin and its Anticancer Effect
Anti-Cancer Agents in Medicinal Chemistry A Review on Leukemia and iPSC Technology: Application in Novel Treatment and Future
Current Stem Cell Research & Therapy Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design The Role of Histone Demethylase GASC1 in Cancer and its Therapeutic Potential
Current Cancer Therapy Reviews DLEU1: A Functional Long Noncoding RNA in Tumorigenesis
Current Pharmaceutical Design IL-2, IL-7 and IL-15 as Immuno-Modulators During SIV/HIV Vaccination and Treatment
Current HIV Research Radiologic Findings of IgG4-Related Disease
Current Immunology Reviews (Discontinued)